https://www.selleckchem.com/products/dt-2216.html
7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%). Data was available for 35 eyes at 1 year. Visual gain was significant, +6 letters (p 0.001) and central subfield thickness (CST) decreased significantly (-108μm, p 0.001) at 1 year. Mean number of injections was 9.3 and mean interval injection was 5.8 weeks. These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. http//www.clinicaltr
Curtir
Comentario
Compartilhar
